WEBULL
WebtradeDownload

Novo Nordisk (NVO) Draws Fresh Valuation Focus, Is It Still 55% Below Fair Value?

Simply Wall St · 1d ago

Novo Nordisk (NYSE:NVO) is back in focus after fresh attention on its obesity and diabetes portfolio, which accounts for most of its US$329.4b in revenue and US$116.4b in net income.

Recent trading has been choppy for Novo Nordisk, with the share price slipping 1.9% on the day to US$46.60 and down 11.1% year to date, yet still posting an 8.9% 90 day gain. However, the 1 year total shareholder return has declined 11.3% and the 3 year total shareholder return is down 49.7%, which points to fading longer term momentum despite shorter term interest returning.

Scan how Novo Nordisk stacks up against other potential breakout opportunities by reviewing the hand picked 49 high quality undervalued stocks that share strong fundamentals and compressed expectations.

Novo Nordisk now trades only modestly below the average analyst target, yet at a steep discount to some intrinsic value estimates. Which reference point best reflects fair value after this recent swing?

Most Popular Narrative: 54.7% Undervalued

Narrative followers see a big gap between Novo Nordisk's last close at $46.60 and a fair value closer to triple that level, so the question shifts from price action to whether the story behind those numbers holds up.

Assuming revenue growth stabilizes at 50% of its historical levels, margins grow from 33% to 35%, and it returns to a P/E of 22 (the current average for the pharmaceutical sector), we see its current fair value at $102.97, making NVO 57.4% undervalued at current prices. We believe the market will continue to undervalue NVO in 2026, but think the share price could reach $62 by the end of the year based solely on the success of its oral GLP-1 products.

Read the complete narrative.

According to MCOInvestors, that $102.97 fair value depends on a specific mix of slower but still solid sales growth, slightly higher margins, and a future earnings multiple that many investors usually reserve for faster growing sectors. Want to see exactly how those three ingredients come together and why this narrative still lands on a deep discount for Novo Nordisk?

Result: Fair Value of $102.97 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, this Novo Nordisk narrative can crack if key assumptions slip, including slower GLP-1 adoption or setbacks in planned adolescent or coramitug approvals.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

With mixed sentiment around Novo Nordisk's recent performance and valuation, you can move quickly and weigh both sides yourself by reviewing the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

If you stop with Novo Nordisk, you risk missing other setups that fit your style. Widen your lens and let data do the heavy lifting.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.